

Type 2 Diabetes in adults (medicines update) Committee meeting 3

Date: 06/07/2023

Location: Virtual

Minutes: Final

NICE National Institute for
Health and Care Excellence

Committee members present:	
Waqaar Shah (Chair)	Present for notes 1 – 8
Chirag Bakhai	Present for notes 1 – 8
Neel Basudev	Present until partway through item 4 and then from partway through item 6
Catherine Bewsey	Present for notes 1 – 8
Mimi Chen	Present for notes 1 – 8
Dan Cuthbertson (Topic Adviser)	Present for notes 1 – 8
Anne Dornhorst	Present for most of each item notes 1 – 8
Hugh Gallagher	Present for notes 1 – 8
Sallianne Kavanagh	Present for notes 1 – 8
Sharon McCarthy	Present for notes 1 – 8
Soon Song	Present for notes 1 – 8
Annette Swinkels	Present for notes 1 – 8
John Turner	Present for notes 1 – 8
Gosia Wamil	Present for notes 1 – 6

In attendance:		
Astrid Aregui	Senior Medical Editor	Present for notes 1 – 8
Rupert Franklin	Senior Guideline Commissioning Manager	Present for notes 1 – 8
James Hawkins	Senior Health Economist	Present for notes 1 – 8
Lina Manounah	Technical Analyst	Present for notes 1 – 8

Caroline Mulvihill	Technical Adviser, Guideline Lead	Present for notes 1 – 8
Tayyaba Mumtaz	Trainee Technical Analyst	Present for notes 1 – 8
Adam O’Keefe	Project Manager	Present for notes 1 – 8
Nancy Pursey	Trainee Technical Analyst	Present for notes 1 – 8
Muksitur Rahman	Health Economist	Present for notes 1 – 8
Joseph Runicles	Information Specialist	Present for notes 1 – 8
Emily Terrazas-Cruz	Senior Research Fellow	Present for notes 1 – 8
George Wood	Technical Analyst	Present for notes 1 – 8

Observers:

Hugo Pedder, NICE Guidelines Technical Support Unit, University of Bristol	For morning session
---	------------------------

Apologies:

Sithembile Thokozile Chinaire	Committee member
Natasha Jacques	Committee member
James Hall	Senior Medical Editor, NICE
Philip Williams	Finance Analyst, NICE
David Wonderling	Head of Health Economics, NICE

1. Welcome, introductions and apologies

The Chair welcomed the Committee members and attendees to the third meeting on Type 2 Diabetes in adults (medicines update). The committee members and attendees introduced themselves. The Chair welcomed an observer from the NICE Guidelines Technical Support Unit at University of Bristol.

The Chair informed the Committee that apologies had been received. These are noted above.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was initial and subsequent treatment of type 2 diabetes.

The Chair asked committee members to verbally declare any new interests, these are noted below:

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Mimi Chen	Committee member, Consultant Diabetologist	Panel member as expert in cardiometabolic for the Global Health Alliance (www.ghahealth.co.uk)	Direct, non-financial professional and personal	Declare and participate. Not specific to the scope of the guideline update
Sallianne Kavanagh	Committee member, Pharmacist	Published educational article for BJN Inform - Gestational Diabetes: Introduction and overview.	Direct financial	Declare and participate. Not specific to the scope of the guideline update
Sallianne Kavanagh	Committee member, Pharmacist	Appointed to Roster of Consultants - Development of technical products for diabetes. World Health Organization (5 year tenure)	Direct, non-financial professional and personal	Declare and participate. Not specific to the scope of the guideline update
Soon Song	Committee member, Consultant Diabetologist	Publication of 'Severe hypoglycaemia presenting to a hospital emergency department: clinical characteristics and mortality outcomes' in Diabetes, Obesity and Metabolism journal.	Direct, non-financial professional and personal	Declare and participate. Not specific to the scope of the guideline update
Soon Song	Committee member, Consultant Diabetologist	Appointed to the Council of Royal College of Physicians of Edinburgh.	Direct, non-financial professional and personal	Declare and participate. Not specific to the scope of the guideline update
Catherine Bewsey	Committee member, Practitioner Psychologist	Part of a working group with Foot in Diabetes Network (FDUK). Co-authored recent position statement - Zero All Preventable (ZAP) amputations: FDUK position statement on "missingness" and reducing major amputations in the acute diabetes foot pathway Joined working group in 2021. Position Statement published in Diabetic Foot Review June 23 –	Direct Non-financial, professional and personal	Declare and participate. Not specific to the scope of the guideline update

		not used as evidence for these guidelines.		
Dan Cuthbertson	Topic Adviser, Consultant Diabetologist	Publication of paper on SGLT2i in Diabetes, Obesity and Metabolism journal: <i>All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes</i> https://doi.org/10.1111/dom.15185	Direct, non-financial professional and personal	Declare and participate Potentially specific to the guideline update but does not pose a conflict to the topics under consideration in the guideline.

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Minutes of previous meeting

The minutes of the previous meeting were accepted as a true and accurate record.

4. Health economics

The Chair introduced Muksit Rahman (MR) who discussed the Health economic review strategy with the committee. MR confirmed inclusion of all UK and OECD country studies from the past 15 years that looked at multiple comparators, and discussed selection of patient populations and comparators with the committee. MR also discussed some elements of the Health economic modelling with the committee.

5. Methods discussion

The Chair introduced Emily Terrazas-Cruz, Senior Systematic Reviewer (ETC) and George Wood, Technical Analyst (GW) who discussed and agreed with the committee which outcomes previously agreed in the review protocol to prioritise for the Network Meta Analysis. ETC explained the rationale for limiting the outcomes to be included but confirmed that all clinical evidence for all outcomes agreed at the review protocol stage will be presented to the committee for its consideration.

6. Review Question 1.1 For different population subgroups, which individual and/or combinations of pharmacological therapies are most clinically and cost effective as initial treatment for the management of type 2 diabetes?

Metformin:

<ul style="list-style-type: none"> • Presentation of clinical evidence • Presentation of health economic evidence
<p>GW presented the clinical evidence identified in support of Review Question 1.1 for Metformin. MR then presented the health economic evidence informing the review question.</p>
<p>7. Review Question 1.1</p> <ul style="list-style-type: none"> • Committee discussion of the evidence • Drafting of recommendations
<p>The committee discussed the evidence presented and their own clinical expertise and drafted updates to the current recommendations accordingly.</p>
<p>8. AOB</p>
<p>AO advised that a full schedule of meetings will be shared shortly.</p>

Date of next meeting: TBC

Location of next meeting: Virtual